<DOC>
	<DOCNO>NCT01837667</DOCNO>
	<brief_summary>The purpose study test safety investigational drug call LB-100 Injection treatment solid tumor , give without docetaxel . LB-100 small molecule laboratory animal study show activity use together drug approve treat type cancer ( chemotherapeutic agent ) . Docetaxel drug approve treatment type cancer ; one trade name docetaxel TaxotereÂ® . The study 2 part . Part 1 : Patients receive injection LB-100 . Part 2 : Patients receive injection LB-100 docetaxel . This first study LB-100 Injection use human .</brief_summary>
	<brief_title>Phase I Study LB-100 With Docetaxel Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Part 1 : Patients histologically cytologically proven progressive metastatic solid tumor fail standard treatment effective treatment available . Part 2 : Patients histologically cytologically proven progressive metastatic solid tumor fail standard treatment effective treatment available , docetaxelnaive patient fail standard treatment tumor docetaxelbased regimen would appropriate . 2 . Part 2 : Patients must docetaxelnaive . 3 . Patients must life expectancy least 12 week . 4 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Patients must men woman &gt; = 18 year age . 6 . Patients must recover acute adverse effect ( exclude alopecia ) prior therapy baseline &lt; = grade 1 prior study entry . 7 . Patients must adequate bone marrow function , define absolute neutrophil count &gt; = 1.5 x 10^9/L platelet count &gt; = 100 x 10^9/L . 8 . Patients must adequate renal function , define serum creatinine &lt; = 1.5 x upper limit normal ( ULN ) institution calculate creatinine clearance [ CockcroftGault method ] must &gt; = 60 mL/min/1.73 m^2 ) . 9 . Patients must adequate hepatic function , define : Part 1 : plasma total bilirubin &lt; = 1.5 mg/dL , alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; = 2.5 X ULN . Part 2 : plasma total bilirubin &lt; = ULN ; ALT and/or AST &lt; = 1.5 X ULN concomitant alkaline phosphatase &lt; = 2.5 X ULN . 10 . Female patient childbearing potential must negative serum urine pregnancy test result time pretreatment screen . 11 . Patients reproductive potential must agree use least one form barrier contraception prior study entry 30 day beyond last administration study drug . 12 . Patients must capable provide informed consent must willing provide write informed consent prior start studyspecific procedure . 1 . Patients may prior chemotherapy , radiotherapy , hormonal therapy , biologic therapy 4 week prior study entry exception mitomycin C nitrosoureas , patient must 6 week prior treatment . For patient treat targeted therapy , 5 halflives therapy ( 28 day , whichever short ) must pass prior enrollment study . 2 . Part 2 : Patients may prior treatment docetaxel . 3 . Part 2 : Patients plasma total bilirubin &gt; ULN ; ALT and/or AST &gt; 1.5 X ULN concomitant alkaline phosphatase &gt; 2.5 X ULN . 4 . Patients may concomitant condition could compromise objective study patient ' compliance ability tolerate therapy complete least 2 cycle therapy , include , limited following : Congestive heart failure uncontrolled angina pectoris , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension , dysrhythmias . Active infection . Unstable diabetes mellitus . Psychiatric disorder may interfere consent and/or protocol compliance . Uncontrolled seizure activity . Prior history inflammatory bowel disease . Prior history pulmonary fibrosis . Prior history cardiomyopathy . 5 . Patients history central nervous system ( CNS ) malignancy . 6 . Pregnant breastfeed woman . 7 . Patients another malignancy past 3 year except : curatively treat nonmelanoma skin cancer , carcinoma situ ( either cervix breast ) require treatment . 8 . Patients know active human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection . 9 . Part 2 : Patients history severe hypersensitivity reaction drug formulate polysorbate 80 ( example , drug formulate polysorbate 80 include , limited : Aranesp , Eprex , Cordarone , vaccine ) . 10 . Part 2 : Patients &gt; = grade 2 peripheral neuropathy . 11 . Patients underlie diagnosis disease state associate increase risk bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>